ArticleThe oncologist2026

Lenvatinib combined with immune checkpoint inhibitors for unresectable, recurrent, or metastatic hepatocellular carcinoma: a real-world study.

Huifang Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.